Altimmune (ALT) Income towards Parent Company (2010 - 2026)

Altimmune (ALT) has reported Income towards Parent Company for 17 consecutive years, with -$22.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Income towards Parent Company fell 15.26% year-over-year to -$22.6 million; the TTM figure through Mar 2026 stood at $12.1 million (up 113.44% YoY), while the FY2025 annual figure was $15.1 million, up 120.13% from the prior year.
• Income towards Parent Company eased to -$22.6 million in Q1 2026 per ALT's latest filing, from $75.9 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $75.9 million in Q4 2025 and bottomed at -$31.6 million in Q4 2023.
• Historically, Income towards Parent Company has averaged -$15.6 million across 5 years, with a median of -$20.7 million in 2023.
• Annual changes were most pronounced in 2023 — Income towards Parent Company tumbled 228.09% — and 2025, when it jumped 427.24%.
• Altimmune's Income towards Parent Company stood at -$9.6 million in 2022, then sank by 228.09% to -$31.6 million in 2023, then climbed by 26.74% to -$23.2 million in 2024, then surged by 427.24% to $75.9 million in 2025, then tumbled by 129.74% to -$22.6 million in 2026.
• Business Quant data shows ALT's Income towards Parent Company at -$22.6 million in Q1 2026, $75.9 million in Q4 2025, and -$19.0 million in Q3 2025.